Zobrazeno 1 - 10
of 103
pro vyhledávání: '"David G Daniel"'
Autor:
Jon McClellan, Lin Sikich, Joan Busner, Robert L. Findling, Jean A. Frazier, Eric A. Youngstrom, David G. Daniel
Publikováno v:
Journal of the American Academy of Child & Adolescent Psychiatry. 62:427-434
Background: Multiple clinical trials of modern antipsychotics have failed in pediatric samples. One possibility for these failures is the use of a primary outcome measure that was developed for adults. Surprisingly, the psychometric properties of pri
Autor:
David G. Daniel, MD, Noah G. Daniel, Donald T. Daniel, Laura Copeland Flynn, MS, Michael H. Allen, MD
Publikováno v:
Current Therapeutic Research, Vol 92, Iss , Pp 100590- (2020)
ABSTRACT: Background: There are few rapidly acting treatments for acute suicidality or treatment-resistant depression. Propofol (2,6-diisopropylphenol) is an intravenous anesthetic agent used in outpatient settings. It is a gamma-aminobutyric acid ty
Externí odkaz:
https://doaj.org/article/366602e60d57412fa1ebafbe007647ca
Autor:
Roger S. McIntyre, David G. Daniel, Eduard Vieta, István Laszlovszky, Pascal J. Goetghebeur, Willie R. Earley, Mehul D. Patel
Publikováno v:
CNS Spectrums. :1-12
Objective To investigate the effect of cariprazine on cognitive symptom change across bipolar I disorder and schizophrenia. Methods Post hoc analyses of 3- to 8-week pivotal studies in bipolar I depression and mania were conducted; one schizophrenia
Autor:
David G Daniel, Alex S Cohen, Dawn Velligan, Phillip D Harvey, Larry Alphs, Michael Davidson, William Potter, Alan Kott, Nina Schooler, Christopher R Brodie, Raeanne C Moore, Pierre Lindenmeyer, Stephen R Marder
Publikováno v:
Schizophrenia Bulletin Open. 4
In contrast to the validated scales for face-to-face assessment of negative symptoms, no widely accepted tools currently exist for remote monitoring of negative symptoms. Remote assessment of negative symptoms can be broadly divided into 3 categories
Autor:
Dileep R. Yavagal, Priyank Khandelwal, Manjot Grewal, Edward Greenberg, Sebastian Koch, Rami Algahtani, Amer M. Malik, Mohammad Rauf A Chaudhry, Robert M. Starke, David G. Daniel, Vasu Saini, Mithilesh Siddu, Muhammad Zeeshan Memon, Joshua Lukas, Taha Nisar, Christopher R. Leon Guerrero, Kathleen M. Burger, Shahram Majidi
Publikováno v:
Journal of Neuroimaging. 31:743-750
Background and purpose The first pass effect has been reported as a mechanical thrombectomy (MT) success metric in patients with large vessel occlusive stroke. We aimed to compare the clinical and neuroimagign outcomes of patients who had favorable r
Autor:
Mehul Patel, György Németh, Willie Earley, David G. Daniel, Suresh Durgam, Balázs Szatmári, Ágota Barabássy, Hua Guo, Henry A. Nasrallah, Yan Zhong
Publikováno v:
Schizophrenia Research. 204:282-288
Although currently approved antipsychotics exert efficacy on positive symptoms of schizophrenia, treatments for negative symptoms remain a major unmet need. Post hoc analyses were used to investigate the possible efficacy of cariprazine in patients w
Publikováno v:
Annals of neurologyReferences. 89(4)
Objective Neurology residency program websites often serve as the initial face of a program for prospective residents early in the application process. We evaluated adult neurology residency program websites to determine their comprehensiveness to id
Publikováno v:
Schizophrenia Bulletin Open. 1
Objective In the current post hoc analyses, we assessed the impact of erratic ratings, a marker of questionable measurement quality, on placebo and drug response and drug-placebo separation in schizophrenia negative symptom trials. Methods Data were
Autor:
Michael H. Davidson, Dawn I. Velligan, Daniel Umbricht, Xingmei Wang, Alan Kott, David G. Daniel, Remy Luthringer, Silvia Zaragoza, Stephen R. Marder, Anzalee Khan
Publikováno v:
Schizophrenia Bulletin Open. 1
Individuals from academia, the pharmaceutical industry, and regulators reevaluated earlier recommendations for the design of clinical trials for negative symptoms based on data from recent large trials. A session in February, 2018 at the Internationa
BACKGROUND: Schizophrenia with predominant negative symptoms represents a significant unmet medical need. New instruments measuring the severity of negative symptoms are being implemented into clinical trials to improve the ability to accurately meas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2eb310c6dd5e69dcd7bc2927aa5ea9c8
https://europepmc.org/articles/PMC6455287/
https://europepmc.org/articles/PMC6455287/